Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

ReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference


ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will virtually present at the Evercore ISI 2024 Emerging Biotech Conference on Thursday, February 29, 2024, at 9:35 a.m. ET.

A webcast of the event will be available in the "News" section of the Company's website at https://renagadetx.com/news/. A replay of the webcast will be archived on the Company's website for 90 days following the presentation date.

About ReNAgade Therapeutics

ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.

To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.

ReNAgade Therapeutics?RNA Without Limits

For more information about the company, its technologies, and its leadership, visit www.renagadetx.com.


These press releases may also interest you

at 23:00
Flourish Ventures, an early-stage venture capital firm with purpose, today announced the appointment of Ravi Kaushik as Executive Director, Head of Asia Investments. Ravi will lead the global firm's fintech investments and portfolio management in...

at 22:17
ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of information and communication technology solutions, today announced that it was honored with 2023 Climate...

at 22:04
During the second phase of the 135th China Import and Export Fair ("Canton Fair" or "the Fair"), a significant memorandum of cooperation was signed between the Fair and the Guangzhou Branch of the National Archives of Publications and Culture,...

at 21:57
Hikvision has released its full-year 2023 financial results, reporting a total revenue of RMB 89.34 billion, up 7.42% year-over-year. Net profit attributable to shareholders of the company was RMB 14.11 billion, achieving a year-over-year (YoY)...

at 21:05
DTEN, a leading provider of video conferencing solutions, is proud to announce that their flagship All-in-One solution, the DTEN D7X series, is now available to purchase in South Korea after it has successfully passed the rigorous certification...

at 20:15
AriBio Co., Ltd. (AriBio) announced authorisation from the European Medicines Agency (EMA) for POLARIS-AD (AR1001-ADP3-US01), a global, phase 3, early Alzheimer's disease clinical trial. EMA now aligns with the U.S. Food and Drug Administration (FDA)...



News published on and distributed by: